English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 110934/141859 (78%)
Visitors : 47676889      Online Users : 1069
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/52412


    Title: 台灣的生技製藥產業：發展、創新與限制
    Other Titles: Taiwan`s Bio-pharmaceutical Industry: Development, Innovation and Limitations
    Authors: 王振寰;陳琮淵
    Keywords: 生技製藥;全球商品鏈;產業升級;創新;台灣
    bio-pharmaceuticals;global commodity chain;industrial upgrading;innovation;Taiwan
    Date: 2009
    Issue Date: 2012-03-08 22:09:27 (UTC+8)
    Abstract: 本文探討台灣生技製藥產業的發展和創新模式。我們認爲解釋台灣生技製藥產業的演化過程，必須考量全球商品鏈、國家機器角色和廠商技術能力之間的搭配關係。本文指出，台灣生技製藥產業發展有兩個主要階段：第一階段在1990年代以前，全球製藥產業被少數公司壟斷，台灣政府雖欲推動生技製藥產業，但缺乏對該創新型產業的理解，且政策規畫未掌握全球商品鏈的分工狀態，致使國家介入方向不明，無法與廠商緊密結合而成果有限。在1990年代中期之後的第二階段，由於國際生技製藥產業朝向將藥物的商品鏈切分開來，並開啟了委外研製模式。在此階段，一方面台灣政府開始大力扶植生技製藥產業，同時放棄以衍生公司主導產業的作法，代之以建立平台來推動；另方面廠商也逐漸切入產業商品鏈的不同區段，而呈現出新的創新類型。不過我們也將指出，此類生技製藥產業的創新模式，雖能成功的與台灣中小企業結構特性結合強化廠商能力，但是這樣的模式卻僅有利於受國家資源支持的廠商，而無法像過去一樣可以「創造」產業和就業。
    The authors investigate the development of Taiwan`s bio-pharmaceutical industry and its pattern of innovation. We argue that in addition to the state factor, elements such as global commodity chains and technological capability are equally essential. Furthermore, we suggest that the development of this industry occurred in two stages. Pre-1990, the state took the lead in promoting bio-pharmaceutical research and production, but the effort failed due to a lack of engagement with private capital and lack of frontier knowledge on the development of the industry. Starting in the mid-1990s, the state became an enabler, and many smaller firms took advantage of the outsourcing practices of large international firms in order to engage in global commodity chains. However, even though the innovation pattern of Taiwan`s bio-pharmaceutical industry fits well with Taiwan`s institutional features, we believe that global links have benefited merely a handful of smaller firms rather than the industry as a whole.
    Relation: 台灣社會學刊,43,158-209。
    Data Type: article
    Appears in Collections:[國家發展研究所] 期刊論文

    Files in This Item:

    File Description SizeFormat
    14-p159-208-陳琮淵-王振寰.pdf1313KbAdobe PDF21688View/Open


    View Licence

    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback